DOCSLIB.ORG

Phenethylamines (58 Substances)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phenethylamines (58 Substances) Phenethylamines (58 substances) R4 R3 R H 5 N R1 R2 R6 R8 R7 CAS Common name Abbreviation Chemical name R R R R R R R R number 1 2 3 4 5 6 7 8 1-benzofuran-4-ylpropan-2- 4-(2-Aminopropyl)benzofuran 4-APB - H CH H H H H −O−CH=CH− amine 3 1-benzofuran-5-ylpropan-2- 5-(2-Aminopropyl)benzofuran 5-APB - H CH H H −CH=CH−O− H H amine 3 1-benzofuran-6-ylpropan-2- 6-(2-Aminopropyl)benzofuran 6-APB - H CH H H −O−CH=CH− H H amine 3 6-(2-Aminopropyl)-2,3- 1-(2,3-dihydro-1-benzofuran-6- 6-APDB 152623-93-3 H CH H H −O−CH −CH − H H dihydrobenzofuran yl)propan-2-amine 3 2 2 2-(3-bromo-2,5-dimethoxy-4- Bromo-STP - - H H H OCH Br CH OCH H methylphenyl)ethanamine 3 3 3 2-(3,4-dimethoxyphenyl)propan- 3,4-Dimethoxyamphetamine - 120-26-3 H CH H H OCH OCH H H 2-amine 3 3 3 2-(3,4-dimethoxyphenyl)-N- 3,4-Dimethoxymethamphetamine DMMA - CH CH H H OCH OCH H H methylpropan-2-amine 3 3 3 3 N,N-dimethyl-1-phenylpropan- NHR = N,N-Dimethylamphetamine, DMA 4075-96-1 1 CH H H H H H H 2-amine dimethyl 3 N,N-dimethyl-1-phenylethan- NHR = N,N-Dimethylphenethylamine - 1126-71-2 1 H H H H H H H 2-amine dimethyl 1-(2-fluorophenyl)propan-2- 2-Fluoroamphetamine 2-FA 1716-60-5 H CH H F H H H H amine 3 1-(3-fluorophenyl)propan-2- 3-Fluoroamphetamine 3-FA 1626-71-7 H CH H H F H H H amine 3 4-FA, 1-(4-fluorophenyl)propan-2- 4-Fluoroamphetamine 459-02-9 H CH H H H F H H PFA amine 3 CAS Common name Abbreviation Chemical name R R R R R R R R number 1 2 3 4 5 6 7 8 N-methyl-1-(3-fluorophenyl) 3-Fluoromethamphetamine 3-FMA 1049677-77-1 CH CH H H F H H H propan-2-amine 3 3 N-methyl-1-(4-fluorophenyl) 4-Fluoromethamphetamine 4-FMA 351-03-1 CH CH H H H F H H propan-2-amine 3 3 N-ethyl-1-(4-methoxyphenyl) p-Methoxyethylamphetamine PMEA 14367-46-5 C H CH H H H OCH H H propan-2-amine 2 5 3 3 Methoxyphenamine, OMMA N-methyl-1-(2-methoxyphenyl) 93-30-1 CH CH H OCH H H H H 2-Methoxymethamphetamine propan-2-amine 3 3 3 p-Methoxymethamphetamine, PMMA N-methyl-1-(4-methoxyphenyl) 3398-68-3 CH CH H H H OCH H H 4-Methoxymethamphetamine propan-2-amine 3 3 3 1-(4-methylphenyl)propan-2- 4-Methylamphetamine 4-MA 22683-78-9 H CH H H H CH H H amine 3 3 N-methyl-5-(2-aminopropyl) N-Methyl-5-APB - - CH CH H H −CH=CH−O− H H benzofuran 3 3 N-methyl-1-(4-methylphenyl) 4-Methylmethamphetamine 4-MMA - CH CH H H H CH H H propan-2-amine 3 3 3 Methylthienylpropamine N-methyl-1-(thiophen-2-yl) Synonyms: Methiopropamine, MPA 7464-94-0 CH CH H Phenyl → thiophenyl1 propan-2-amine 3 3 Methedrene, Syndrax Phenethylamine PEA 1-phenylethan-2-amine 64-04-0 H H H H H H H H N-methyl-2-phenylpropan-1- Phenpromethamine - 93-88-9 CH H CH H H H H H amine 3 3 2-Phenylpropanamine, β-Me-PEA 2-phenylpropan-1-amine 582-22-9 H H CH H (β-methylphenethylamine) 3 2-Thiophen-2-yl-ethylamine - 2-(thiophen-2-yl)ethan-2-amine - H H H Phenyl → thiophenyl1 2,4,5-Trimethoxyamphetamine 1-(2,4,5-tirmethoxyphenyl)- TMA-2 1083-09-6 H CH H OCH H OCH OCH H propan-2-amine 3 3 3 3 2,4,6-Trimethoxyamphetamine 1-(2,4,6-trimethoxyphenyl) TMA-6 15402-79-6 H CH H OCH H OCH H OCH propan-2-amine 3 3 3 3 1 The substance has been placed in the phenethylamine category to illustrate the slight modification to the parent phenethylamine group. CAS Common name Abbreviation Chemical name R R R R R R R R number 1 2 3 4 5 6 7 8 H N-methyl-1-(3-fluorophenyl) H CO N 3-Fluoromethamphetamine 3-FMA 1049677-77-1 CH CH H H F H H H 3 propan-2-amine 3 3 R3 N-methyl-1-(4-fluorophenyl) R OCH 4-Fluoromethamphetamine 4-FMA 351-03-1 CH CH H H H F H H 1 3 propan-2-amine 3 3 R2 N-ethyl-1-(4-methoxyphenyl) p-Methoxyethylamphetamine PMEA 14367-46-5 C2H5 CH3 H H H OCH3 H H propan-2-amine CAS Methoxyphenamine, OMMA N-methyl-1-(2-methoxyphenyl) Common name Chemical name R1 R2 R3 93-30-1 CH CH H OCH H H H H number 2-Methoxymethamphetamine propan-2-amine 3 3 3 p-Methoxymethamphetamine, PMMA N-methyl-1-(4-methoxyphenyl) 2C-C 4-chloro-2,5-dimethoxyphenethylamine 88441-14-9 Cl H H 3398-68-3 CH CH H H H OCH H H 4-Methoxymethamphetamine propan-2-amine 3 3 3 1-(4-chloro-2,5-dimethoxyphenyl)-N-[(2- C H OCH 1-(4-methylphenyl)propan-2- 2C-C-NBOMe - Cl H CH2 6 5 3 4-Methylamphetamine 4-MA 22683-78-9 H CH H H H CH H H methoxyphenyl)methyl]-2-ethanamine amine 3 3 2C-D 4-methyl-2,5-dimethoxyphenethylamine 24333-19-5 CH H H N-methyl-5-(2-aminopropyl) 3 N-Methyl-5-APB - - CH CH H H −CH=CH−O− H H benzofuran 3 3 1-(4-methyl-2,5-dimethoxyphenyl)-N-[(2- H CH C H OCH N-methyl-1-(4-methylphenyl) 2C-D-NBOMe - CH3 2 6 5 3 4-Methylmethamphetamine 4-MMA - CH CH H H H CH H H methoxyphenyl)methyl]-2-ethanamine propan-2-amine 3 3 3 2C-E 4-ethyl-2,5-dimethoxyphenethylamine 71539-34-9 C H H H Methylthienylpropamine 2 5 N-methyl-1-(thiophen-2-yl) Synonyms: Methiopropamine, MPA 7464-94-0 CH CH H Phenyl → thiophenyl1 propan-2-amine 3 3 2C-F 4-fluoro-2,5-dimethoxyphenethylamine 207740-15-6 F H H Methedrene, Syndrax 2C-G 3,4-dimethyl-2,5-dimethoxyphenethylamine 207740-18-9 CH CH H Phenethylamine PEA 1-phenylethan-2-amine 64-04-0 H H H H H H H H 3 3 2C-H 2,5-dimethoxyphenethylamine 3600-86-0 H H H N-methyl-2-phenylpropan-1- Phenpromethamine - 93-88-9 CH H CH H H H H H amine 3 3 2C-I 4-iodo-2,5-dimethoxyphenethylamine 69587-11-7 I H H 2-Phenylpropanamine, β-Me-PEA 2-phenylpropan-1-amine 582-22-9 H H CH H 2C-IP 4-isopropyl-2,5-dimethoxyphenethylamine - i-Pr (isopropyl) H H (β-methylphenethylamine) 3 2C-N 4-nitro-2,5-dimethoxyphenethylamine 261789-00-8 NO2 H H 2-Thiophen-2-yl-ethylamine - 2-(thiophen-2-yl)ethan-2-amine - H H H Phenyl → thiophenyl1 2C-O-4 4-isopropoxy-2,5-dimethoxyphenethylamine - isopropoxy H H 2,4,5-Trimethoxyamphetamine 1-(2,4,5-tirmethoxyphenyl)- TMA-2 1083-09-6 H CH H OCH H OCH OCH H propan-2-amine 3 3 3 3 2C-P 4-propyl-2,5-dimethoxyphenethylamine 207740-22-5 C3H7 H H 2,4,6-Trimethoxyamphetamine 1-(2,4,6-trimethoxyphenyl) TMA-6 15402-79-6 H CH H OCH H OCH H OCH 2C-SE 4- methylseleneo-2,5-dimethoxyphenethylamine - SeCH3 H H propan-2-amine 3 3 3 3 2C-T 4-methylthio-2,5-dimethoxyphenethylamine 61638-09-3 SCH3 H H CAS Common name Chemical name R R R number 1 2 3 2C-T-2 4-ethylthio-2,5-dimethoxyphenethylamine 207740-24-7 SC2H5 H H 2C-T-4 4-isopropylthio-2,5-dimethoxyphenethylamine 207740-25-8 i-PrS (isopropylthio) H H 2C-T-7 4-propylthio-2,5-dimethoxyphenethylamine 207740-26-9 SC3H7 H H 2C-TFM 4-trifluoromethyl-2,5-dimethoxyphenethylamine 159277-08-4 CF3 H H 2C-V 4-ethenyl-2,5-dimethoxyphenethylamine - CH=CH2 H H 2C-YN 4-ethynyl-2,5-dimethoxyphenylethylamine 752982-24-4 C≡CH H H 1-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) 25H-NBOMe - H H CH C H OCH methyl] ethanamine 2 6 5 3 25I- NBOMe, 1-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2- 919797-19-6 I H CH C H OCH 2C-I-NBOMe methoxyphenyl) methyl]ethanamine 2 6 5 3 OCH3 NH2 R1 OCH3 Common name Abbreviation Chemical name CAS number R1 2,5-Dimethoxy-4-chloroamphetamine DOC 1-(4-chloro-2,5-dimethoxyphenyl)-propan-2-amine 123431-31-2 Cl 2,5-Dimethoxy-4-iodoamphetamine DOI 1-(4-iodo-2,5-dimethoxyphenyl)-propan-2-amine 82864-02-6 I CAS Common name Chemical name Structure number H N-Benzyl-1-phenethylamine N-Benzyl-1-phenethylamine 38235-77-7 N O 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2- NH2 Bromo-Dragonfly 502759-67-3 amine Br O Camfetamine N-methyl-3-phenyl-norbornan-2-amine 92499-19-9 NH O 2C-B-fly 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1] NH2 178557-21-6 benzofuran-4-yl)ethanamine Br O O 3C-B-fly 1-(8-bromo-2,3,6,7-tetrahydrobenzo[2,3-f][1] NH - 2 benzofuran-4-yl)-propan-2-amine Br O NH M-ALPHA, 1-Methylamino-1-(3,4- 1-Methylamino-1-(3,4-methylenedioxyphenyl) - methylenedioxyphenyl)propane propane O O.
Load more

Recommended publications
  • Neurotransmitter Resource Guide
    NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................
    [Show full text]
  • Methylphenidate Hydrochloride
    Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatograph
    applied sciences Article Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatography Mass Spectrometry, Electrospray and Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Bo-Hong Chen, Ju-Tsung Liu, Hung-Ming Chen, Wen-Xiong Chen and Cheng-Huang Lin * Department of Chemistry, National Taiwan Normal University, 88 Sec. 4 Tingchow Road, Taipei 11677, Taiwan; [email protected] (B.-H.C.); [email protected] (J.-T.L.); [email protected] (H.-M.C.); [email protected] (W.-X.C.) * Correspondence: [email protected]; Tel.: +886-2-7734-6170; Fax: +886-2-2932-4249 Received: 18 April 2018; Accepted: 19 June 2018; Published: 22 June 2018 Abstract: Characteristic mass fragmentation of 20 phenethylamine/tryptamine standards were investigated and compared by means of matrix assisted laser desorption/time-of-flight mass spectrometry (MALDI/TOFM), gas chromatography–electron ionization–mass spectrometry (GC-EI/MS) and liquid chromatography–electrospray ionization/mass spectrometry (LC-ESI/MS) + methods. As a result, three characteristic peaks ([M] and fragments from the Cβ-Cα bond breakage) were found to be unique and contained information useful in identifying 2C series compounds based on the GC-EI/MS method. We found that the protonated molecular ion ([M+H]+) and two types of fragments produced from the α-cleavage and β-cleavage processes were useful mass spectral information in the rapid screening and confirmation of phenethylamine and tryptamine derivatives when ESI/MS and MALDI/TOFMS methods were applied. This assay was successfully used to determine samples that contain illicit drugs. Keywords: phenethylamine; tryptamine; MALDI/TOFMS; GC-EI/MS; LC-ESI/MS 1.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • N-Alkylation of Phenethylamine and Tryptamine Gerta Cami-Kobeci, Paul A
    Bioorganic & Medicinal Chemistry Letters 15 (2005) 535–537 N-Alkylation of phenethylamine and tryptamine Gerta Cami-Kobeci, Paul A. Slatford, Michael K. Whittlesey and Jonathan M. J. Williams* Department of Chemistry, University of Bath, Claverton Down, Bath BA2 7AY, UK Received 28 October 2004; revised 17 November 2004; accepted 18 November 2004 Available online 24 December 2004 Abstract—A clean and efficient method for the N-alkylation of tryptamine and phenethylamine, employing alcohols as the alkyl- ating agents, has been developed. The reaction proceeds via catalytic electronic activation, involving an iridium catalyst which activates the alcohol by borrowing hydrogen from the substrate, returning it later in the catalytic cycle. Some examples of N-heterocyclisation have been performed employing a diol as the substrate. Ó 2004 Elsevier Ltd. All rights reserved. The ability to prepare a large number of synthetically NMe2 useful and pharmacologically active compounds, either H N OH by traditional or high throughput methods, is becoming Me S O O HN increasingly important. Herein we report an efficient, N atom economic, one-pot method for the N-alkylation H of tryptamine and phenethylamine, giving water as the OH only by-product. Sumatriptan Nylidrin Figure 1. The tryptamine sub-structure is present in numerous naturally occurring and synthetic compounds, many of which exhibit important pharmacological activity. For mercially available iminophosphorane 3.5 The reaction example, a number of 5-alkyltryptamine derivatives proceeds via a strategy
    [Show full text]
  • Chapter 4: MDMA
    MDMA 4 ERROL YUDKO (±)3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy,” E, Adam, X, XTC) is a methamphetamine analogue. It has hallucinogenic, psychostimu- lant, and multiple behavior-altering activities (Green et al., 1995). Although it was discovered serendipitously in 1912 by Merck Pharmaceuticals, its use as a psychotherapeutic/recreational drug was unknown until the late 1970s. By the early 1980s, as the popularity of the “rave party” increased so did use of MDMA. In 1985, prior to its classification as a Schedule I drug, it was being evaluated for its use in psychotherapy. A fearful Congress and Drug Enforcement Administration (DEA) successfully petitioned for its classifica- tion as a Schedule I compound with no evidence that it was at all harmful. Recreational use of MDMA has been on the rise for the past 20 years (Peroutka, 1987; Schuster et al., 1998; Pope et al., 2001). Increases in the rate of MDMA use have continued despite reductions in the use of other substances (Johnston et al., 2001a,b). This is an international trend (Abraham et al., 1998; Hibell et al., 2000; McPherson and Afsarifard, Chapter 3 of this book). Although there have been occasional deaths indirectly caused by the use of MDMA (Henry et al., 1992), it is widely considered by its users to be a “safe” drug. The illusion of safety stems from lack of the obvious negative effects that other amphetamine-type compounds induce. MDMA does not cause an increase in aggressive behavior, and its users do not experience paranoid schizophrenia. According to the Drug Abuse Warning Network (DAWN) less than 0.3% of drug-related emergency room visits are due to MDMA.
    [Show full text]
  • Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com Ce4less.Com
    Hallucinogens And Dissociative Drug Use And Addiction Introduction Hallucinogens are a diverse group of drugs that cause alterations in perception, thought, or mood. This heterogeneous group has compounds with different chemical structures, different mechanisms of action, and different adverse effects. Despite their description, most hallucinogens do not consistently cause hallucinations. The drugs are more likely to cause changes in mood or in thought than actual hallucinations. Hallucinogenic substances that form naturally have been used worldwide for millennia to induce altered states for religious or spiritual purposes. While these practices still exist, the more common use of hallucinogens today involves the recreational use of synthetic hallucinogens. Hallucinogen And Dissociative Drug Toxicity Hallucinogens comprise a collection of compounds that are used to induce hallucinations or alterations of consciousness. Hallucinogens are drugs that cause alteration of visual, auditory, or tactile perceptions; they are also referred to as a class of drugs that cause alteration of thought and emotion. Hallucinogens disrupt a person’s ability to think and communicate effectively. Hallucinations are defined as false sensations that have no basis in reality: The sensory experience is not actually there. The term “hallucinogen” is slightly misleading because hallucinogens do not consistently cause hallucinations. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com How hallucinogens cause alterations in a person’s sensory experience is not entirely understood. Hallucinogens work, at least in part, by disrupting communication between neurotransmitter systems throughout the body including those that regulate sleep, hunger, sexual behavior and muscle control. Patients under the influence of hallucinogens may show a wide range of unusual and often sudden, volatile behaviors with the potential to rapidly fluctuate from a relaxed, euphoric state to one of extreme agitation and aggression.
    [Show full text]
  • Detection of Phenethylamine, Amphetamine, and Tryptamine Imine By-Products from an Acetone Extraction
    Detection of Phenethylamine, Amphetamine, and Tryptamine Imine By-Products from an Acetone Extraction Mary A. Yohannan* and Arthur Berrier U.S. Department of Justice Drug Enforcement Administration Special Testing and Research Laboratory 22624 Dulles Summit Court Dulles, VA 20166 [email: mary.a.yohannan -at- usdoj.gov] ABSTRACT: The formation of imine by-products from phenethylamines, amphetamines, and tryptamines upon an acetone extraction is presented. These imine by-products were characterized using GC/MSD and exhibited preferential cleavage at the α-carbon of the alkyl chain. Further characterization of the imine by-products of phenethylamine and tryptamine was done using IR and NMR. KEYWORDS: phenethylamine, tryptamine, imine, acetone, schiff base, drug chemistry, forensic chemistry In most forensic laboratories, the solvents used to extract at the α-carbon on the alkyl chain. In addition to GC/MS, the drugs are chosen based upon their solubility properties and their imines formed from phenethylamine base and tryptamine base ability to not interact with the drug. In fact, there are very few were characterized by Fourier transform-infrared spectroscopy publications where a solvent used to extract a drug reacts with (FTIR) and nuclear magnetic resonance (NMR) spectroscopy. the drug and forms by-products [1-3]. This laboratory recently discovered that an additional Experimental component was formed when acetone was used to extract a Solvents, Chemicals, and Materials sample containing a known tryptamine. Analysis by gas Acetone was ACS/HPLC grade from Burdick and Jackson chromatography/mass spectroscopy (GC/MS) of the acetone Laboratories (Muskegon, MI). Phenethylamine base and extract yielded an extra peak in the total ion chromatogram that tryptamine base were obtained from Sigma-Aldrich Chemicals was approximately half the abundance of the known tryptamine (Milwaukee, WI).
    [Show full text]
  • Recommended Methods for the Identification and Analysis Of
    Vienna International Centre, P.O. Box 500, 1400 Vienna, Austria Tel: (+43-1) 26060-0, Fax: (+43-1) 26060-5866, www.unodc.org RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES Laboratory and Scientific Section United Nations Office on Drugs and Crime Vienna RECOMMENDED METHODS FOR THE IDENTIFICATION AND ANALYSIS OF AMPHETAMINE, METHAMPHETAMINE AND THEIR RING-SUBSTITUTED ANALOGUES IN SEIZED MATERIALS (revised and updated) MANUAL FOR USE BY NATIONAL DRUG TESTING LABORATORIES UNITED NATIONS New York, 2006 Note Mention of company names and commercial products does not imply the endorse- ment of the United Nations. This publication has not been formally edited. ST/NAR/34 UNITED NATIONS PUBLICATION Sales No. E.06.XI.1 ISBN 92-1-148208-9 Acknowledgements UNODC’s Laboratory and Scientific Section wishes to express its thanks to the experts who participated in the Consultative Meeting on “The Review of Methods for the Identification and Analysis of Amphetamine-type Stimulants (ATS) and Their Ring-substituted Analogues in Seized Material” for their contribution to the contents of this manual. Ms. Rosa Alis Rodríguez, Laboratorio de Drogas y Sanidad de Baleares, Palma de Mallorca, Spain Dr. Hans Bergkvist, SKL—National Laboratory of Forensic Science, Linköping, Sweden Ms. Warank Boonchuay, Division of Narcotics Analysis, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand Dr. Rainer Dahlenburg, Bundeskriminalamt/KT34, Wiesbaden, Germany Mr. Adrian V. Kemmenoe, The Forensic Science Service, Birmingham Laboratory, Birmingham, United Kingdom Dr. Tohru Kishi, National Research Institute of Police Science, Chiba, Japan Dr.
    [Show full text]
  • Drugs of Abuseon September Archived 13-10048 No
    U.S. DEPARTMENT OF JUSTICE DRUG ENFORCEMENT ADMINISTRATION WWW.DEA.GOV 9, 2014 on September archived 13-10048 No. v. Stewart, in U.S. cited Drugs of2011 Abuse EDITION A DEA RESOURCE GUIDE V. Narcotics WHAT ARE NARCOTICS? Also known as “opioids,” the term "narcotic" comes from the Greek word for “stupor” and originally referred to a variety of substances that dulled the senses and relieved pain. Though some people still refer to all drugs as “narcot- ics,” today “narcotic” refers to opium, opium derivatives, and their semi-synthetic substitutes. A more current term for these drugs, with less uncertainty regarding its meaning, is “opioid.” Examples include the illicit drug heroin and pharmaceutical drugs like OxyContin®, Vicodin®, codeine, morphine, methadone and fentanyl. WHAT IS THEIR ORIGIN? The poppy papaver somniferum is the source for all natural opioids, whereas synthetic opioids are made entirely in a lab and include meperidine, fentanyl, and methadone. Semi-synthetic opioids are synthesized from naturally occurring opium products, such as morphine and codeine, and include heroin, oxycodone, hydrocodone, and hydromorphone. Teens can obtain narcotics from friends, family members, medicine cabinets, pharmacies, nursing 2014 homes, hospitals, hospices, doctors, and the Internet. 9, on September archived 13-10048 No. v. Stewart, in U.S. cited What are common street names? Street names for various narcotics/opioids include: ➔ Hillbilly Heroin, Lean or Purple Drank, OC, Ox, Oxy, Oxycotton, Sippin Syrup What are their forms? Narcotics/opioids come in various forms including: ➔ T ablets, capsules, skin patches, powder, chunks in varying colors (from white to shades of brown and black), liquid form for oral use and injection, syrups, suppositories, lollipops How are they abused? ➔ Narcotics/opioids can be swallowed, smoked, sniffed, or injected.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]